What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• After demand for GLP‑1 drugs (semaglutide, tirzepatide) surged, many compounding pharmacies started making and selling compounded versions. The FDA has taken the position that compounding copies of FDA‑approved GLP‑1 drugs (i.e., products that are essentially the same as Ozempic/Wegovy or Mounjaro/Zepbound) is unlawful and raises safety/quality concerns, and it has issued warnings and stepped up enforcement and coordination with state boards of pharmacy.
• Legally operating options now are: (a) prescribing and dispensing FDA‑approved GLP‑1 drugs through licensed prescribers and pharmacies; (b) compounding pharmacies that follow federal/state compounding rules (503A patient‑specific compounding) or 503B outsourcing facilities that comply with CGMP — provided they are not compounding “copies” of approved products and meet regulatory requirements.

What the FDA did (brief)

• Warned the public and issued warning letters to certain compounders selling unapproved copies of GLP‑1 medications.
• Said compounding pharmacies should not make products that are essentially copies of approved, marketed drugs (FDA’s “no-compounding of copies” policy).
• Raised safety concerns (potency, sterility, contamination, incorrect dosing, mislabeled products) and worked with state pharmacy boards, which led some compounders to stop or modify their operations.

Who is still operating legally (and how to tell)

1. FDA‑approved manufacturers and products (recommended)

   • Novo Nordisk: Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for chronic weight management). These are FDA‑approved, made by the original manufacturer, and dispensed by normal pharmacies with a prescription.
   • Eli Lilly: Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight management). Also FDA‑approved and made under manufacturer quality controls. Why use them: Manufactured under FDA standards (label accuracy, sterility, consistent potency), predictable dosing and safety profile.

2. Licensed prescribers + licensed pharmacies

   • A prescription from your doctor, endocrinologist, or a reputable telehealth clinic (that does a medical evaluation) filled at a licensed pharmacy (retail chains like CVS, Walgreens, or national mail‑order pharmacies) is the standard legal route.

3. Compounding pharmacies — only in narrow, legal circumstances

   • 503A compounding pharmacies: may legally compound patient‑specific prescriptions when no suitable FDA‑approved product is available. They must have a patient‑specific order and follow state board rules.
   • 503B outsourcing facilities: can produce larger batches but must comply with FDA current good manufacturing practices (CGMP). Even 503A/503B operations are not allowed to compound “essentially copies” of approved drugs.
   • Many compounding shops that were making semaglutide/tirzepatide copies have stopped after FDA/state action; some that remain are operating legally because they either produce truly patient‑specific formulations or otherwise follow legal limits.

How to protect yourself / questions to ask

• Ask whether the product is an FDA‑approved brand (Ozempic, Wegovy, Mounjaro, Zepbound) and who the manufacturer is. If it’s not from the named manufacturer, ask why.
• If using a compounding pharmacy, ask whether it’s a 503A (patient‑specific) or 503B (outsourcing) facility, request their licenses, and ask for a certificate of analysis (COA) and sterile testing results.
• Prefer prescriptions filled by established pharmacies or manufacturer‑supplied products. Avoid online offers for cheap “semaglutide” or “tirzepatide” where manufacturer and origin aren’t clear.

If you want, I can:

• Help you check a specific product name or pharmacy (give me the name and location/website), or
• Walk through how to verify a telemedicine clinic or pharmacy before you order.